Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA – Get Free Report) COO Ross Moat sold 75,608 shares of Kiniksa Pharmaceuticals International stock in a transaction that occurred on Friday, October 30th. The stock was sold at an average price of $93.13, for a total transaction of $7,041,373.04. Following the transaction, the chief operating officer directly owned 10,294 shares in the company, valued at $958,680.22. The trade was a 88.02% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Ross Moat also recently made the following trade(s):
- On Monday, November 2nd, Ross Moat sold 27,977 shares of Kiniksa Pharmaceuticals International stock. The shares were sold at an average price of $92.36, for a total transaction of $2,583,955.72.
Kiniksa Pharmaceuticals International Stock Performance
Shares of NASDAQ:KNSA opened at $88.34 on Friday. The company has a 50 day moving average price of $80.18 and a two-hundred day moving average price of $61.10. The company has a market capitalization of $6.89 billion, a PE ratio of 67.95 and a beta of 0.07. Kiniksa Pharmaceuticals International, plc has a 52 week low of $37.02 and a 52 week high of $98.48.
Kiniksa Pharmaceuticals International (NASDAQ:KNSA – Get Free Report) last announced its quarterly earnings results on Tuesday, October 27th. The company reported $0.56 earnings per share for the quarter, topping analysts’ consensus estimates of $0.37 by $0.19. Kiniksa Pharmaceuticals International had a net margin of 11.58% and a return on equity of 17.27%. The company had revenue of $285.97 million for the quarter, compared to analysts’ expectations of $260.66 million. On average, sell-side analysts forecast that Kiniksa Pharmaceuticals International, plc will post 1.30 earnings per share for the current year.
Wall Street Analysts Forecast Growth
Several brokerages recently commented on KNSA. Wall Street Zen downgraded Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “buy” rating in a research note on Sunday, July 12th. Weiss Ratings cut Kiniksa Pharmaceuticals International from a “buy (b-)” rating to a “hold (c-)” rating in a research note on Wednesday, October 28th. The Goldman Sachs Group boosted their target price on Kiniksa Pharmaceuticals International from $90.00 to $101.00 and gave the company a “buy” rating in a research note on Wednesday, October 28th. Wells Fargo & Company increased their price target on Kiniksa Pharmaceuticals International from $87.00 to $110.00 and gave the stock an “overweight” rating in a report on Wednesday, October 28th. Finally, Wedbush raised their price target on Kiniksa Pharmaceuticals International from $99.00 to $102.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 28th. Seven research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $100.57.
Get Our Latest Stock Report on Kiniksa Pharmaceuticals International
Institutional Inflows and Outflows
Institutional investors have recently bought and sold shares of the stock. Lisanti Capital Growth LLC boosted its holdings in shares of Kiniksa Pharmaceuticals International by 48.0% in the third quarter. Lisanti Capital Growth LLC now owns 129,250 shares of the company’s stock valued at $9,643,000 after buying an additional 41,945 shares during the period. Jacobi Capital Management LLC acquired a new stake in shares of Kiniksa Pharmaceuticals International during the third quarter worth $48,000. Ethic Inc. acquired a new stake in shares of Kiniksa Pharmaceuticals International during the third quarter worth $726,000. Pictet Asset Management Holding SA raised its holdings in shares of Kiniksa Pharmaceuticals International by 41.3% during the third quarter. Pictet Asset Management Holding SA now owns 860,228 shares of the company’s stock worth $64,182,000 after acquiring an additional 251,578 shares during the period. Finally, AlphaCentric Advisors LLC bought a new stake in Kiniksa Pharmaceuticals International in the 3rd quarter valued at $596,000. Institutional investors own 53.95% of the company’s stock.
About Kiniksa Pharmaceuticals International
Kiniksa Pharmaceuticals International plc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for patients with serious and often under-treated immunological diseases. The company’s research and development efforts are centered on targeting specific pathways involved in inflammation and immune-system dysfunction.
Kiniksa’s principal commercial product is ARCALYST (rilonacept), an interleukin-1 inhibitor. In the United States, ARCALYST is approved for reducing the risk of recurrence in patients with recurrent pericarditis and for the treatment of cryopyrin-associated periodic syndromes, including familial cold autoinflammatory syndrome and Muckle-Wells syndrome, in eligible patients.
The company also maintains a pipeline of investigational medicines designed to address autoimmune and inflammatory conditions.
Read More
- Five stocks we like better than Kiniksa Pharmaceuticals International
- Google’s Credit Backstop May Be TeraWulf’s Biggest Advantage
- Could the Midterms Revive Medicare for All? 3 Healthcare Stocks to Watch
- Qualcomm Beat Earnings, But Its Fastest-Growing Businesses Have a Catch
- Oil, Uranium, or Renewables? 3 Energy Plays for a Changing Market
Receive News & Ratings for Kiniksa Pharmaceuticals International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kiniksa Pharmaceuticals International and related companies with MarketBeat.com's FREE daily email newsletter.
